New standard regimen for ovarian cancer?

Clinicians need a good reason not to use it after the head-to-head trial, expert commentator says

Carboplatin-pegylated liposomal doxorubicin-bevacizumab should be a new standard regimen for women with recurrent platinum-sensitive ovarian cancer suitable for antiangiogenic treatment, say the authors of a clinical trial.